Ocera Therapeutics Inc (NASDAQ:OCRX) currently trades at $0.570 which is about -5.00% lower than the 52-week high of $3.90. The trading volume at ready counter moved to 1.82M shares as compared to 541,851.00 shares average traded volume. The stock failed to get pushed above the $0.65 barrier, the intraday high, after opening at $0.65. Analysts have a consensus target price of $9.00 in the 12-month period. Its market capitalization has now reached to $3.86M.

Ocera Therapeutics Inc (NASDAQ:OCRX) was dropped to Underweight from Equal Weight at Barclays. It has earned a consensus Strong buy rating, according to Zacks Investment Research. No analyst has rated the stock with a sell rating, 0 have assigned a hold rating, Zero says it’s a buy and 5 have assigned a strong buy rating to the company.

Ocera Therapeutics Inc (OCRX) on December 7, 2016 announced it has completed enrollment in its Phase 2b STOP-HE Study evaluating the efficacy, safety and tolerability of Ornithine Phenylacetate (OCR-002) in hospitalized patients with Hepatic Encephalopathy (STOP-HE).

“This is a critical milestone for the Company,” said Linda Grais, M.D., Chief Executive Officer of Ocera. “Hepatic encephalopathy (HE) is a serious and costly condition, causing increasing numbers of hospitalizations every year. The current standard of care is limited, and we believe that physicians are eager for more effective therapeutic options to help patients improve faster and return to their normal mental status.”

“We anticipate that STOP-HE will deliver a rich source of global data from approximately 230 patients that should provide a greater understanding about the disease and its response to treatment, and inform the further development path of OCR-002,” said Stan Bukofzer, M.D., Chief Medical Officer of Ocera. “We believe OCR-002 could become a first-line and foundational therapy for treating hospitalized patients with HE and expect to report top-line data in the first quarter of 2017.”

STOP-HE Study Design

STOP-HE is a placebo-controlled, randomized, double-blind clinical trial designed to evaluate the safety, pharmacokinetics and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized cirrhotic patients with elevated ammonia. Either OCR-002 or placebo was administered to patients intravenously for up to five days along with standard of care. The OCR-002 arm was dosed with 20, 15, or 10 grams over 24 hours based on the patient’s degree of liver impairment in order to normalize drug exposure. The primary efficacy endpoint is time to meaningful clinical improvement in HE symptoms as analyzed using a 0.05 level 2-sided log-rank test of equality of time to event curves with 80% power.